Navigation Links
How does Fu-Zheng-Jie-Du-Decoction act on PTEN expression in hepatocellular carcinoma?
Date:1/16/2008

Many hepatocellular carcinoma (HCC) patients in China may be treated with Traditional Chinese medicine (TCM). Some say it works, others doubt its effectiveness. These stated that a research group in China had found TCM can down-regulate the expression of PTEN in HCC, which may suppress tumor cell growth and regulate tumor cell invasion and metastasis.

A research article published on January 7, 2008 in the World Journal of Gastroenterology (volume 14, issue 1) addresses this problem. The research group imbedded hepatoma carcinoma tissue in the livers of 48 male athymic mice. The mice were distributed randomly into two groups: The chemotherapy group was treated by intragastric administration with FT207 (Tegafur). The TCM group was treated by intragastric administration with FZJDT (complex prescription of Chinese crude drug) that had been deliquated into 3 kinds of density as the low, middle, and high.

Four weeks later, the researchers found the TCM group had distinct superiority in their survival rate compared with the chemotherapy group. There was less tumor metastasis in the livers of the TCM group than in the chemotherapy group. Particularly the results of immunohistochemistry showed the intensity of PTEN (Phosphatase and Tensin Homolog deleted on Chromosome 10) in the TCM group was higher than in the chemotherapy group.

PTEN was recently identified as a tumor suppressor gene by three American research teams. They found PTEN may suppress tumor cell growth and regulate tumor cell invasion and metastasis through inhibiting many signal pathways of cell proliferation.

FZJDT has been widely used to treat HCC for years in The First Affiliated Hospital of Sun Yat-Sen University. Just what is the mechanism of the Chinese herbs that strengthens the body's resistance and removes toxic substances? Our research showed TCM could markedly increase expression of PTEN in the athymic mice, compared with the chemotherapy group treated with F
'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. iNOS expression may links chronic biliary inflammation to malignant transformation
2. Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix GeneChip(R) Technology
3. Facial expressions have greater impact on kids with bipolar disorder
4. Flip-flopping gene expression can be advantageous
5. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
6. New study shows that therapeutic gene expression can be sustainable for 1 year
7. 10th Anniversary of Revolutionary Teaching Approach that Offers the Severely Disabled the Gift of Self-Expression - Through Painting
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. A new chemotherapeutic target for hepatocellular carcinoma
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...eille Guiliano’s bestseller ‘French Women Don’t Ge...nment figures, 5.9 million of France's 63.4 millio.... The figures have got the French government scra...e ways to come back to the former image of the sve...
...amin supplements and low fat dairy products in Bri...inding which was published// in The Journal of the...finding consumption of vitamin pills for a prolong...ality rate by 5% and low fat dairy may hamper the ...
...tain’s pay deals given by pay review bodies of the... millions of public sector workers across the coun...specially negative, in the medical sector. Healt... announced that GPs or family doctors will get a z...
Busting the Exam Blues
Other Medicine News:Health News:UK’s Health Services Totterin 2Health News:Busting the Exam Blues 2Health News:Busting the Exam Blues 3Health News:Busting the Exam Blues 4
(Date:5/21/2008)...ong Group of Leading Cancer Centers ...f., May 21 /- Endocare, Inc...ompany focused on the,development of minimally inv...tional radiologists for tissue and tumor ablation,...vasive method of freezing cancerous tumors,to dest...
(Date:5/20/2008)...- Today at the,World Congre...led "New,Perspectives in Atrial Fibrillation Manag... Cardiology, St George,s University of London,hig...ENA clinical trial,results, as the way forward in ...most common form of cardiac arrhythmia., To view ...
(Date:5/20/2008)... Digestive Disease Week(R) 2008, NATICK, Mass. an...on,Scientific Corporation (NYSE: BSX ) today anno...patient registry documenting favorable safety,and ...isualization System,which offers extensive visual...istry were presented by Yang K. Chen, M.D., Divisi...
(Date:5/20/2008)...y at Digestive Disease Week -, CAMBRIDGE, Mass. a...wood Pharmaceuticals, Inc. (formerly Microbia, Inc...ay announced the presentation of data,from a Phase...tudy,assessing the safety and efficacy of linaclot...alysis of these data indicate that linaclotide met...
Breaking Medicine Technology:Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 2Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 3Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 4Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 18422 1Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 18422 2Scientists identify gatekeepers of breast cancer transition to invasive disease 18418 1Scientists identify gatekeepers of breast cancer transition to invasive disease 18418 2More efficient fuel cells thanks to a new catalyst 3185 1More efficient fuel cells thanks to a new catalyst 3185 2More efficient fuel cells thanks to a new catalyst 3185 3More efficient fuel cells thanks to a new catalyst 3185 4Protein May Trigger Colon Cancer 18411 1
...007 - Late breaking data,presented at the American... Sessions showed that, when used investigationally...combination with,metformin provided significant gl...d over 54 weeks in patients with type 2,diabetes. ...resented also showed that JANUVIA significantly im...
...E)--June 25, 2007--Gilead,Sciences, Inc. (Nasdaq:G...linical trial evaluating the company,s once-daily,...rate or tenofovir,DF) 300 mg as a potential treatm... met its primary efficacy endpoint. The data show,...daily antiviral,drug Hepsera(R) (adefovir dipivoxi...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5
...r System combines precision with ease of operation...ns. The pneumatic motor powered system developed f...rocedures includes a drill, sagittal saw (extended...th available), reciprocating saw (extended length ...
Elmed Retract - Robot an single arm instrument, with extra long (10") horizontal extension for improved cephalad and anterior retraction. Retract - Robot (Retractor system) was designed to assist sur
Fortitude as a unique complement to the spinal concepts family of products.
As a unique complement to the spinal concepts family of products.
Medicine Products: